Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report

C‐ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement has been detected in patients with advanced non‐small cell lung cancer (NSCLC). Although ROS1 tyrosine kinase inhibitors (TKIs) provide a survival benefit for patients with ROS1‐rearranged advanced NSCLC, subsequent therapy remains limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chi‐Hao, Su, Po‐Lan, Hsu, Che‐Wei, Chu, Chang‐Yao, Lin, Chien‐Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590892/
https://www.ncbi.nlm.nih.gov/pubmed/34623764
http://dx.doi.org/10.1111/1759-7714.14175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590892/
https://www.ncbi.nlm.nih.gov/pubmed/34623764
http://dx.doi.org/10.1111/1759-7714.14175

Ejemplares similares